Kindred Biosciences Coverage Initiated at BMO Capital Markets (KIN)
Investment analysts at BMO Capital Markets began coverage on shares of Kindred Biosciences (NYSE:KIN) in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.
Kindred Biosciences (NYSE:KIN) opened at 10.79 on Monday. Kindred Biosciences has a one year low of $8.75 and a one year high of $14.065. The stock has a 50-day moving average of $11.77 and a 200-day moving average of $11.77. The company’s market cap is $162.4 million.
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company focused on pets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.